Company Focus
Chiesi Farmaceutici
Latest Chiesi Farmaceutici News
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced financial results for the six months ended June 30, 2025. 16 September 2025
Related News
Insights
Company Spotlight
The company operates as a U.S.-based cardiovascular biopharmaceutical developer with additional corporate functions outside California to support clinical operations, regulatory activity, and commercialization planning.
Latest News & Features of interest to Chiesi Farmaceutici
Biotechnology
In a slow news last week a mixed batch of clinical trials results featured. First, US biotech Ultragenyx announced disappointing Phase III results for its Osteogenesis Imperfecta (OI) candidate setrusumab, under development with Mereo BioPharm. Then InflaRx presented a new analysis of vilobelimab for pyoderma gangrenosum, and Pfizer disclosed a death in a long term Hympavzi study after thrombotic stroke. Also of note, after previous setbacks, the US Food and Drug Administration (FDA) granted approval for Vanda Pharmaceuticals’ motion sickness drug Nereus (tradipitant). 4 January 2026
Pharmaceutical
US gastrointestinal (GI) and rare diseases specialist has announced financial guidance for full year 2026, which pleased investors and sent its shares up nearly 27% to $4.27. 3 January 2026
Biotechnology
US biotech Corcept Therapeutics said the American medicines regulator has issued a complete response letter rejecting its application for relacorilant in hypertension secondary to hypercortisolism, knocking the company’s shares down more than 50% earlier in the week. 2 January 2026
Biotechnology
US biotech Ultragenyx Pharmaceutical In this week revealed that it has completed the rolling submission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA), seeking approval for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for glycogen storage disease Type Ia (GSDIa). 2 January 2026
Biotechnology
US gene therapy company Regenxbio’s clemidsogene lanparvovec has a plausible pathway to US Food and Drug Administration (FDA) approval in Hunter syndrome, although the decision will likely hinge on whether biomarker reductions can be convincingly linked to meaningful clinical outcomes, experts tell the insights investigative news team at GlobalData. 31 December 2025
Biotechnology
German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has outlined multiple data analyses of the Phase III study for vilobelimab in pyoderma gangrenosum (PG). 30 December 2025
Pharmaceutical
Privately-held Italian drugmaker Italfarmaco and Japanese drugmaker JCR Pharmaceuticals have announced an exclusive licensing agreement for the development and commercialization of givinostat in Japan. 30 December 2025
Biotechnology
US biotech Ultragenyx Pharmaceutical saw its shares tumble over 43% to $19.41 yesterday, after it announced results from the Phase III Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). 30 December 2025
Biotechnology
Despite the US Food and Drug Administration’s (FDA) acceptance of Inovio’s Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with recurrent respiratory papillomatosis (RRP), Monday was still a bleak day for the Pennsylvania firm. 29 December 2025
Biosimilars
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has secured full and exclusive global rights for Hulio (biosimilar adalimumab) from Fujifilm Kyowa Kirin Biologics (FKB). 29 December 2025
Latest In Brief for Chiesi Farmaceutici
Pharmaceutical
Swiss pharma company Santhera Pharmaceuticals announced that the Swiss Agency for Therapeutic Products (Swissmedic), has approved Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. 15 January 2026
Latest Relevant Ones To Watch News
Hong Kong-listed Sino Biopharmaceutical is to buy fellow Chinese firm Hangzhou Hygieia Biomedical. 13 January 2026
19 December 2025
15 December 2025
12 December 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze